Genzyme given US thumbs up to manufacture Thymoglobulin in France

By Dan Stanton

- Last updated on GMT

Genzyme given US thumbs up to manufacture Thymoglobulin in France
Sanofi has received US FDA approval to make its kidney transplant rabbit-derived antibody product Thymoglobulin from a facility in Lyon,France.

Genzyme Polyclonals, a subsidiary of French Pharma Giant Sanofi, manufactures the product used in the prevention and treatment of acute rejection in organ transplantation from its site in Lyon,France, and has now received validation from the US Food and Drug Administration (FDA) after applying to the agency in December 2012.

The US has become the 44th country to validate the site which Sanofi says can produce lots of Thymoglobulin to treat over 15,000 patients per year.

"This approval is a source of immense satisfaction for our teams on a daily basis, working to the very many patients awaiting transplant can benefit from our treatments, in the best conditions,"​ site manager Stéphane Piquand said.

Thymoglobulin is an anti-thymocyte globulin (ATG) - an infusion of rabbit-derived antibodies against human T cells.

Related topics Upstream Processing Facilities

Related news

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers